SCHEMBL5607148

SCHEMBL5607148

NC(Cc1ccc(NC(=O)c2ccccc2Cl)cc1)C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMO Q99835 9/20 0.70
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
NPC1 O15118 1/20 0.56
MAPT P10636 1/20 0.56
MAPK1 P28482 1/20 0.56
RAB9A P51151 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
KLKB1 P03952 1/20 0.54
ALPI P09923 1/20 0.54
PKM P14618 1/20 0.54
PTGS1 P23219 1/20 0.54
XIAP P98170 1/20 0.54
SLC7A5 Q01650 1/20 0.54
ITGB1 P05556 3/20 0.54
ITGA4 P13612 3/20 0.54
JAK2 O60674 1/20 0.52
TYK2 P29597 1/20 0.52
GRM4 Q14833 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5078480 1.00 SMO (0.70) SMOKMT2AMEN1NPC1MAPT
SCHEMBL27515653 0.85 ITGB1 (0.64) ITGB1ITGA4ITGB3ITGAVITGA2B
SCHEMBL5230799 0.85 ITGB1 (0.64) ITGB1ITGA4ITGB3ITGAVITGA2B
SCHEMBL5606984 0.84 SLC7A5 (0.54) SMOKMT2ANPC1RAB9AALPI
SCHEMBL5607021 0.84 FFAR1 (0.65) SMOKMT2AMEN1NPC1MAPT
SCHEMBL5607007 0.84 FFAR1 (0.65) SMOKMT2AMEN1NPC1MAPT
SCHEMBL5606988 0.84 SLC7A5 (0.54) SMOKMT2ANPC1RAB9AALPI
Hydrochloric Acid SCHEMBL5224621 0.84 ITGB1 (0.63) ITGB1ITGA4ITGB3ITGAVITGA2B
Hydrochloric Acid SCHEMBL28097879 0.84 ITGB1 (0.63) ITGB1ITGA4ITGB3ITGAVITGA2B
SCHEMBL7769029 0.82 ITGB3 (0.67) KMT2AMEN1NPC1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP SMO 2844/4885KMT2A 3688/4885MEN1 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.